| 摘要 |
An isolated and biologically pure strain of oncolytic bacteria derivable from human intestinal microflora, selected from Escherichia coli, Streptococcus faecalis and other intestinal bacterial species, is used in a bacterial formulation for the treatment of cancer, which comprises, together with at least one pharmaceutically acceptable diluent, carrier or adjuvant, either (i) at least three such oncolytic strains of bacteria, or (ii) at least one such oncolytic strain of bacteria selected from four specified strains. In a method for the early diagnosis of cancer in a human, a human feces-derived Escherichia coli or Streptococcus faecalis sample is incubated in vitro with a standard culture containing a predetermined number of cancer cells, for a predetermined time, after which the number of interacted and/or non-interacted cancer cells present is counted, the extent of interaction being preferably calibrated against the extent of interaction between a control preparation of such oncolytic bacteria, incubated under the same conditions with the standard culture of cancer cells. 27 |
